Viewing Study NCT06620302

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:39 AM
Ignite Modification Date: 2026-02-10 @ 10:10 PM
Study NCT ID: NCT06620302
Status: RECRUITING
Last Update Posted: 2025-10-24
First Post: 2024-09-26
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
Sponsor: Children's Oncology Group
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Childhood Fibrolamellar Carcinoma View
None Recurrent Childhood Fibrolamellar Carcinoma View
None Recurrent Childhood Malignant Solid Neoplasm View
None Recurrent Fibrolamellar Carcinoma View
None Recurrent Malignant Solid Neoplasm View
None Refractory Childhood Fibrolamellar Carcinoma View
None Refractory Childhood Malignant Solid Neoplasm View
None Refractory Fibrolamellar Carcinoma View
None Refractory Malignant Solid Neoplasm View
Keywords: